This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jounce Therapeutics, Inc.
Drug Names(s): ICOS, JTX2011, JTX 2011
Description: JTX-2011 is a humanized monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells. JTX-2011 has a dual mechanism of action, stimulating T effector cells and selectively reducing intra-tumoral T regulatory cells, thereby shifting the balance of T cells in a tumor toward anti-tumor activity.
Jounce and Celgene
In July 2016,Jounce Therapeutics announced a global strategic collaboration withCelgene Corporation focused on developing and commercializinginnovative immuno-oncology treatments for patients with cancer. The collaborationincludes options on Jounces lead product candidate, JTX-2011, targeting ICOS, and upto four early-stage programs to be selected from a defined pool of B cell, T regulatorycell and tumor-associated macrophage targets emerging from the Jounce TranslationalScience Platform and an additional option to equally share a checkpoint immunooncologyprogram. Post option exercise, Jounce will lead global development and U.S.commercialization for JTX-2011 and one additional collaboration program.
Under the terms of the collaboration, Jounce will receive an upfront payment of $225 million and a $36 million equity investment from Celgene. Jounce will also receive regulatory, development, and net sales milestone payments and tiered royalties on...See full deal structure in Biomedtracker
Partners: Celgene Corporation
Additional information available to subscribers only: